Previous 10 | Next 10 |
Sundial Growers (NASDAQ: SNDL ) -26% on CEO exit . More news on: Sundial Growers Inc., Briggs & Stratton Corporation, Intelsat S.A., , Stocks on the move, Read more ...
DVB Technologies (NASDAQ: DBVT ) slips 8% premarket on light volume in reaction to its global offering of an aggregate of 7.5M ordinary shares via the following: More news on: DBV Technologies S.A., Healthcare stocks news, Stocks on the move, , Read more ...
Montrouge, France, January 30, 2020 DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “ Company ”) (Euronext: DBV – ISIN: FR001...
Montrouge, France, January 29, 2020 DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position DBV Technologies (the “ Company ”) (Euronext: D...
UK-based Allergy Therapeutics ( OTCPK:AGYTF ) announces the publication of positive data on its peanut allergy vaccine candidate in The Journal of Allergy and Clinical Immunology. More news on: Allergy Therapeutics plc, Aimmune Therapeutics, Inc., DBV Technologies S.A., Healthcare sto...
Aimmune Therapeutics, Inc. ( AIMT ) has risen more than 80% since early September (from under $20 to near $34 now) in anticipation of the FDA approval of Palfrozia – previously known as AR-101 – as the first ever approved treatment for children who suffer from peanut allergies. B...
AMF REGULATED INFORMATION Montrouge, France, January 15, 2020 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today ...
Apellis Pharmaceuticals ( APLS ) reported positive results from a Phase 3 clinical trial, PEGASUS , evaluating pegcetacoplan (APL-2) in adults with paroxysmal nocturnal hemoglobinuria. The trial pitted the drug directly against Alexion's Soliris and offered positive results. As per the resu...
Aimmune Therapeutics ' (NASDAQ: AIMT) share price has gained 11% over the past month as the company waits for the Food and Drug Administration to issue an approval decision on its very first drug, one that represents the theme of its three-drug pipeline: treatments to address food allerg...
Shares of DBV Technologies (NASDAQ: DBVT) are up 11% at 12:40 p.m. EST on positive long-term data for the biotech 's peanut allergy medication Viaskin Peanut. Children in the phase 3 Pepites clinical trial were able to continue on the drug in an extension study called People. After three y...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...